Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Nov 24;205(12):2863–2872. doi: 10.1084/jem.20080713

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2008 Spaapen et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 7. — The effector function of CD19^L-mHag–specific clone 21. (A) Granzyme B production of clone 21 in response to recipient (Rt) or donor (Do) EBV-LCLs (LCLs). (B) The lysis of recipient EBV-LCLs or donor EBV-LCLs by clone 21 in the absence or presence of 15-mer CD19^L-peptide at an effector/target ratio of 50:1. The error bars represent the SEM of duplicate cultures. (C) IFN-γ response of clone 21 toward CD19⁺ malignant cells from 18 B-CLL patients. The mHag genotypes of the patients were determined by partial sequencing of the chromosomal DNA extracted from PBMCs. The mean and SEM are shown for the indicated number of patient samples. The difference between the HLA-matched CD19^L-positive patients and the others was statistically significant (*, P < 0.05). (D) The lysis of HLA-DQB1*02 and CD19^L-positive (n = 3) and CD19^L-negative (n = 2) B-CLL samples by clone 21 at different effector/target ratios. Error bars indicate the SEM of the different B-CLL samples.